title: The future of direct-to-consumer clinical genetic tests.
abstract: In light of the meeting of the US Food and Drug Administration (FDA) in March 2011 to discuss the regulation of clinical direct-to-consumer (DTC) genetic tests, we have invited five experts to consider the best means of overseeing the ordering and interpretation of these tests. Should these tests be regulated? If so, who, if anyone, should communicate results to consumers?
authors.affiliation: Medco Research Institute, Medco Health Solutions, Inc., Bethesda, Maryland 20814, USA. felix_frueh@medco.com
authors.forename: Felix W
authors.initials: FW
authors.lastname: Frueh
authors.forename: Henry T
authors.initials: HT
authors.lastname: Greely
authors.forename: Robert C
authors.initials: RC
authors.lastname: Green
authors.forename: Stuart
authors.initials: S
authors.lastname: Hogarth
authors.forename: Sue
authors.initials: S
authors.lastname: Siegel
mesh_terms: D019411:Clinical Laboratory Techniques / Q000639:trends; D003132:Commerce / Q000379:methods / Q000639:trends; D003142:Communication; D003256:Community Participation / Q000639:trends*; D005820:Genetic Testing / Q000331:legislation & jurisprudence / Q000379:methods / Q000639:trends*; D006801:Humans; D010817:Physician-Patient Relations; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence / Q000639:trends